Peter W. Lewis

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• PD27-04 EPIGENETIC BIOMARKERS PREDICT RESPONSE TO ANDROGEN DEPRIVATION AND IDENTIFY NOVEL THERAPEUTIC TARGETS IN PROSTATE CANCER

  The Journal of Urology · 2026-04-27

• IP49-25 HISTONE-MODIFYING ENZYMES IN ANDROGEN-DEPRIVED PROSTATE CANCER: EZH1 AS A SYNERGISTIC THERAPEUTIC TARGET

  The Journal of Urology · 2026-04-27

• Abstract 5715: Histone-modifying enzymes in androgen-deprived prostate cancer: EZH1 as a synergistic therapeutic target

  Cancer Research · 2026-04-03

• Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer

  Neoplasia · 2026-02-19

• Abstract PR034: NSD2 inhibition in hormone sensitive prostate cancer synergizes with androgen deprivation therapy to improve tumor response

  Cancer Research · 2026-01-20

• Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer

  Frontiers in Endocrinology · 2026-01-12 · 1 citations

• SUZ12–Nucleic Acid Interactions Constrain PRC2 Activity to Maintain Targeted Gene Silencing Essential to Diffuse Midline GliomaPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-07-19 · 1 citations